ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc. · NCT07783542
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–79 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 200
- US sites recruiting
- 14
- Study start
- August 21, 2026
- Record last updated
- September 24, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Being studied: ORKA-002; Placebo
Conditions: Hidradenitis Suppurativa (HS)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Has signs and symptoms of HS for at least 6 months;
- Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III;
- Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic antibiotics for HS, demonstrated intolerance to systemic antibiotics for HS, or has a contraindication to systemic antibiotics for HS
Exclusion Criteria
- Presence of any other active skin disease or condition that may interfere with the assessment of HS;
- Diagnosis or suspected diagnosis of autoimmune diseases or inflammatory conditions other than HS
Recruiting US locations
Oruka Therapeutics Investigative Site
Birmingham, AL 35244
Site contact: Oruka Investigative Site · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Fountain Valley, CA 92708
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Los Angeles, CA 90045
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Cromwell, CT 06416
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Sandy Springs, GA 30328
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Chicago, IL 60602
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
New Orleans, LA 70115
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Canton, MI 48187
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
New Brighton, MN 55112
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Omaha, NE 68144
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Portland, OR 97201
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Dallas, TX 75246
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Missouri City, TX 77459
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
San Antonio, TX 78213
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Study contacts (from the official record)
- Oruka Clinical Trials Information · 781-560-0299 · clinicaltrials@orukatx.com
Similar studies in Alabama
All dermatology studies in Alabama →- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 2–11